Takeda signs option deal for TKI inhibitor; Enveda’s $55M raise

Plus, news about IN8bio, Rezolute, BeiGene and NewBridge:

Takeda, Ascentage ink option deal: The deal involves a compound called olverembatinib, which Takeda

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Denver banker and philanthropist Don Sturm stayed engaged until the end – The Cannabist

Related Articles Don Sturm, founder of ANB Bank and a major donor to the University of Denver, died on Saturday at age 92. “He was

August 19, 2024

Risk Adjusted Net Present Value: What is the current valuation of Wave Life Sciences’s WVEN-531

Share this article The revenue for WVEN-531 is expected to reach an annual total of $37 mn by 2034 globally based off GlobalData’s Expiry Model.

December 5, 2023

What Does The New Tracking Guidance from HHS Mean for Digital Marketers’ Technology Decisions?

John Berndt, SVP of Health North America, Valtech Also known as the Kennedy–Kassebaum Act, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) defines

September 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.